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Background: There is an urgent need for the discovery of new anti-malarial drugs and combination therapy. A
combinatorial approach protects each drug from the development of resistance and reduces generally the overall
transmission rate of malaria. Statins, the inhibitors of 3-hydroxy-3-methylglutaryl-Coenzyme A reductase and a family
of lipid-lowering drugs, have in vitro anti-malarial properties, and more specially atorvastatin. However, atorvastatin
has a short elimination half-life (14 hours) and an efficient combination of anti-malarial drugs must associate a drug
with a short elimination half-life and a drug with a long elimination half-life. The objective of the present work was
to identify new potential partners among standard new anti-malarial drugs with long elimination half-life, such as
lumefantrine, piperaquine, pyronaridine and atovaquone, to improve the in vitro activity of atorvastatin against
different Plasmodium falciparum strains to treat uncomplicated malaria.
Methods: In vitro interaction of atorvastatin in combination with lumefantrine, piperaquine, pyronaridine and
atovaquone was assessed against 13 P. falciparum strains by isotopic test.
Results: Atorvastatin showed additive effects with pyronaridine, piperaquine and lumefantrine. Atorvastatin
increased the in vitro activity of lumefantrine and piperaquine at concentrations expected in clinical observations.
The average IC50 values of lumefantrine decreased significantly from 31.9 nM to 20.5 nM (a decrease of 35.7%) in
combination with 1 μM of atorvastatin.
Conclusions: Even though in vitro data indicate that atorvastatin improved the activity of lumefantrine and
piperaquine, the same may not necessarily be true in vivo. Piperaquine, a new drug with long terminal elimination
half-life, is currently a very promising anti-malarial drug.
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Over the past 20 years, many strains of Plasmodium
falciparum have become resistant to chloroquine and
other anti-malarial drugs [1]. In 2002, the World Health
Organization (WHO) recommended that artemisinin-
based combination therapy (ACT) be used to treat all ca-
ses of uncomplicated malaria and that artesunate should
be used as the first-line treatment for severe malaria in* Correspondence: bruno.pradines@free.fr
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unless otherwise stated.2011. Several recent studies have reported clinical failures
or extended parasite clearance times in Cambodia [2-4].
There is an urgent need for the discovery of new anti-
malarial drugs and combination therapy. A combinator-
ial approach protects each drug from the development
of resistance and reduces generally the overall transmis-
sion rate of malaria [5].
Statins, the inhibitors of 3-hydroxy-3-methylglutaryl-
Coenzyme A reductase (HMG-CoA reductase) and a
family of lipid-lowering drugs, have in vitro anti-malarial
properties [6,7]. Moreover, atorvastatin improved the in
vitro activity of mefloquine [8], quinine [9], dihydroarte-
misinin [10] and Proveblue®, a methylene blue prepar-
ation that complies with the European Pharmacopoeial Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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of recognized toxicity [11], at the plasma concentra-
tions expected in clinical observations in patients tak-
ing 80 mg of atorvastatin daily (0.1 to 0.5 μM) [12].
However, atorvastatin used alone failed to prevent death
from cerebral malaria or to affect the parasitaemia of in-
fected mice [13-15]. Atorvastatin combined with meflo-
quine (a long half-life drug) led to a significant delay in
mouse death and had an effect on the onset of cerebral
malaria symptoms [16]. However, the mice died of severe
anaemic malaria. The combination of dihydroartemisinin
and atorvastatin was effective as a therapeutic scheme for
improving mouse survival but less effective for cytokine
modulation, which is associated with protection against
cerebral malaria [17]. In a therapeutic intraperitonal-
scheme, the combination of atorvastatin and dihydroar-
temisinin versus dihydroartemisinin alone resulted in a
significant delay in mouse death and had an effect on the
onset of cerebral malaria symptoms and on the level of
parasitaemia. The experimental conditions did not prevent
death. Atorvastatin failed to improve in vivo efficacy of
quinine in cerebral malaria [17]. Atorvastatin has a short
elimination half-life (14 hours) compared to proguanil
(24 hours), atovaquone (31–73 hours), chloroquine (two
to three days), lumefantrine (four to six days), pyronari-
dine (six days), mefloquine (six to 41 days), or piperaquine
(22 days). A combination of anti-malarial drugs must as-
sociate a drug with a short elimination half-life and a drug
with a long elimination half-life. However, this is a debat-
able concept because the long half-life drug is exposed for
a significant period of time to select parasite resistance.
The objective of the present work was to identify new
potential partners among standard new anti-malarial
drugs with long elimination half-life, such as lumefan-
trine, piperaquine, pyronaridine, and atovaquone, to im-
prove the in vitro activity of atorvastatin against different
P. falciparum strains to treat uncomplicated malaria.
Methods
Strains of Plasmodium falciparum
Thirteen parasite strains or clones from a wide panel of
countries (Cambodia, Cameroon, Gabon, the Gambia,
Indochina, Republic of Comoros, Republic of the Congo,
Senegal, Sierra Leone, and Uganda) were maintained in
culture in RPMI 1640 (Invitrogen, Paisley, UK) supple-
mented with 10% human serum (Abcys SA, Paris, France)
and buffered with 25 mM HEPES and 25 mM NaHCO3.
Parasites were grown in type A+ human red blood cells
under controlled atmospheric conditions (10% O2, 5%
CO2, and 85% N2) at 37°C with a humidity of 95%. All
strains were synchronized twice with sorbitol before use
[18]. Clonality was verified using PCR genotyping of poly-
morphic genetic markers, msp1, msp2, and microsatellite
loci [19,20]. The potentiation evaluation of each strainwas assessed in three independent experiments, as previ-
ously described [21].
Drugs
Stock solutions were prepared by dilution in methanol
for piperaquine, pyronaridine and atovaquone; and in
ethanol for lumefantrine. Final concentrations ranged
from 0.05 to 318 nM for lumefantrine, 0.1 to 10,000 nM
for atovaquone, 0.16 to 100 nM for pyronaridine and
0.78 to 994 nM for piperaquine. A total of 25 μL of
stock solution of each concentration was distributed in
duplicate or triplicate into Falcon 96-well flat bottom
plates. Plates were dried overnight. Atorvastatin stock so-
lution was prepared extemporately with 1% DMSO (v/v)
in RPMI and diluted in sterile distilled water for final con-
centrations included between 0.006 and 32 μM. Aliquots
of 25 μl of atorvastatin solution were distributed into
Falcon 96-well plates pre-dosed with anti-malarial agents.
In vitro assay
The 50% inhibitory concentration (IC50), i.e., the drug
concentration corresponding to 50% of the uptake of
3H-hypoxanthine by the parasites in drug-free control
wells, was determined by non-linear regression analysis
of log-dose/response curves. Data were expressed as the
geometric mean IC50, and 95% confidence intervals (95%
CIs) were calculated. Each anti-malarial drug was serial
diluted and combined with a static concentration of
atorvastatin to obtain IC50 for each anti-malarial drug.
Ten various atorvastatin concentrations were used to con-
struct the isobolograms. Isobolograms were constructed
by plotting a pair of fractional IC50s for each combination
of anti-malarial treatment and atorvastatin. Fractional
IC50s were calculated by dividing the atorvastatin fixed
concentration by its IC50 alone, and these data were plot-
ted on the horizontal axis. The corresponding fractional
IC50s of each classical anti-malarial treatment were calcu-
lated by dividing the combined IC50s of each classical
anti-malarial treatment with the atorvastatin by the IC50
of the anti-malarial treatment alone, and these data were
plotted on the vertical axis. A straight diagonal isobolo-
gram indicates an additive effect. Curves above or below
the diagonal indicate antagonistic or synergistic effects, re-
spectively. Results close to the diagonal are considered to
be additive.
Statistical analysis
The effects of atorvastatin at concentrations ranging from
0.1 to 1 μM, without intrinsic effects, were analysed with
respect to the lumefantrine, piperaquine, pyronaridine,
and atovaquone activity. These concentrations were re-
levant to atorvastatin plasma concentrations that are
achievable in patients taking 80 mg of atorvastatin daily
(0.1 to 0.5 μM). Statistical analysis was performed using R
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used to compare the medians of different matched groups,
and the Wilcoxon test was used to compare the medians
of two matched under-groups.
Results
Atorvastatin showed additive effects with piperaquine,
lumefantrine and pyronaridine (Figure 1).
Static concentration of atorvastatin affected significantly
the in vitro activity of lumefantrine and piperaquine. The
average IC50 values of lumefantrine decreased significantly
from 31.9 nM to 28.1 nM (a decrease of 11%) in combin-
ation with 0.12 μM of atorvastatin, 26.3 nM (a decrease of
17.6%) in combination with 0.25 μM of atorvastatin,
24.6 nM (a decrease of 24.8%) in combination withFigure 1 In vitro combinations of atorvastatin with lumefantrine, pipera0.5 μM of atorvastatin and 20.5 nM (a decrease of 35.7%)
in combination with 1 μM of atorvastatin, at atorvastatin
plasma concentrations expected from clinical observations
in patients taking 80 mg of atorvastatin daily (Table 1).
The average IC50 values of piperaquine decreased sig-
nificantly from 61.1 nM to 52.5 nM (a decrease of 14.1%)
in combination with 0.5 μM of atorvastatin and 51.2 nM
(a decrease of 16.2%) in combination with 1 μM of
atorvastatin.
Atorvastatin did not significantly affect the IC50 values
of pyronaridine or atovaquone.
Discussion
Atorvastatin improved strongly the in vitro activity of
dihydroartemisinin [10], mefloquine [8], quinine [9], andquine and pyronaridine against 13 Plasmodium falciparum strains.
Table 1 Inhibitory activities of lumefantrine, piperaquine, pyronaridine and atovaquone alone and in combination
with atorvastatin against 13 strains of Plasmodium falciparum
Anti-malarial drugs Lumefantrine Piperaquine Pyronaridine Atovaquone
IC50 mean (nM) P-value IC50 mean (nM) P-value IC50 mean (nM) P-value IC50 mean (μM) P-value
Alone 31.9 ± 15.1 61.1 ± 15.5 30.3 ± 9.6 3.79 ± 2.0
+ 0.12 μM Atorvastatin 28.1 ± 15.1 0.0068 59.5 ± 19.7 NS 28.9 ± 9.2 NS 3.35 ± 1.5 NS
+ 0.25 μM Atorvastatin 26.3 ± 12.4 0.0019 61.7 ± 18.7 NS 29.1 ± 10.1 NS 3.35 ± 1.6 NS
+ 0.5 μM Atorvastatin 24.6 ± 11.7 0.0019 52.5 ± 17.5 0.0146 28.4 ± 10.2 NS 3.23 ± 1.3 NS
+ 1 μM Atorvastatin 20.5 ± 11.0 0.0009 51.2 ± 19.2 0.0244 26.9 ± 10.0 NS 2.93 ± 1.3 NS
NS if P-value > 0.05.
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and piperaquine. Atorvastatin demonstrated antagonistic
effects with anti-malarial drugs whose resistance involves
the P. falciparum chloroquine resistance transporter gene
(pfcrt), such as chloroquine, monodesethylamodiaquine
[9]. In addition, atorvastatin didn’t affect significantly the
in vitro activity of pyronaridine whose resistance seems to
interact also with pfcrt (unpublished observations). A
decrease in P. falciparum susceptibility to lumefantrine,
mefloquine or dihydroartemisinin is associated with poly-
morphisms in the genes encoding the multidrug resistance
(MDR)-like proteins, such as Pgh1, encoded by pfmdr1
(P. falciparum multidrug resistance 1), or in copy num-
bers of this gene [22-25]. Atorvastatin is an inhibitor of
the human phosphoglycoprotein (PgP), an efflux protein
involved in cancer cells [26-28]. Pgh1 could be a target for
atorvastatin in P. falciparum parasites. However, in vitro
responses to piperaquine seem to be not associated with
polymorphisms in pfcrt gene [29] and in pfmdr1 [30] or
copy number of pfmdr1 [31], but associated with repeat
polymorphisms in the low-complexity regions of a P.
falciparum ABC transporter, pfmdr6 [32]. Atorvastatin
seems to improve the in vitro activity of anti-malarial
drugs whose resistance involves preferentially ABC trans-
porters such as pfmdr1 and pfmdr6 and don’t affect
or reduce the activity of drugs whose resistance involves
preferentially pfcrt.
Atorvastatin given with mefloquine and dihydroar-
temisinin prevents cerebral malaria in a mouse model
[16,17]. However, the mice that did not die of cerebral
malaria died of severe anaemic malaria. Atorvastatin
strongly protects endothelial cells against P. falciparum-
induced collateral damage, cell apoptosis and endothelial
barrier permeabilization [33]. Atorvastatin can be used
to reduce P. falciparumcyto-adherence to endothelial
cells; cyto-adherence and the inflammatory burst are the
key events of pathogenesis in severe human malaria. In
mice with Plasmodium berghei ANKA cerebral malaria,
lovastatin reduces pro-inflammatory cytokines in the
brain and prevents cognitive impairment [34].
Another hypothesis that could explain differences in
vitro activity and in vivo efficacy is the role the cytochromeP450 enzyme. Most of the anti-malarial drugs are metabo-
lised by the cytochrome P450 enzyme. Chloroquine, quin-
ine, mefloquine, amodiaquine, lumefantrine, piperaquine,
artemisinin derivatives and atorvastatin are metabolised
by CYP3A4/A5 [35,36]. Artesunate and artemisinin are
also metabolised by CYP2A6 and CYP2B6 [35]. Dihy-
droartemisinin is metabolised by UGT1A9 and UGT2B7
[35]. In addition, chloroquine and amodiaquine are me-
tabolised by CYP2C8 [35]. Atorvastatin induces the ac-
tivity of CYP2C8 and that of CYP3A4 but to a lesser
way [37]. By increasing the P450 activity, atorvastatin
could increase the catabolism of some anti-malarial drugs
and reduce or sometimes increase (proguanil) the efficacy
of the drug.
Even though in vitro data indicate that atorvastatin
improved the activity of lumefantrine and piperaquine,
the same may not necessarily be true in vivo. Pipera-
quine, a new drug with long terminal elimination half-
life, is currently a very promising anti-malarial drug.
These observations support calls for an in vivo evalu-
ation of combination of atorvastatin with lumefantrine
and piperaquine in a mouse model to treat uncompli-
cated malaria.
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